ArticleOncotarget2015

Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.

Loredana Vesci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.